Biotech | September 26, 2021
U.S. FDA completes inspection of Biocon Biologics, Malaysia with six observations
The company does not expect the outcome of this inspection to impact its plans
The company does not expect the outcome of this inspection to impact its plans
Zydus' Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy
The company is the Clinical Research Organisation of Caplin Point Laboratories
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
Assam is home to more than 1,700 species of medicinal plants
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Subscribe To Our Newsletter & Stay Updated
